首页> 美国卫生研究院文献>Diabetes Therapy >Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1

【2h】

Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1

机译：杜格鲁肽单药治疗与格列美脲相比在未经口服降糖药物治疗的中国初治2型糖尿病患者中的疗效和安全性：AWARD-CHN1的事后分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Demographic and baseline characteristics of OAM-naïve Chinese patients

机译：没有OAM的中国患者的人口统计学和基线特征

著录项

期刊名称 Diabetes Therapy
作者
Yi Ming Li; Li Hui Zhang; Xue Jun Li; Bin Zhang; Jia Ning Hou; Nan Wei Tong;
展开▼
作者单位

展开▼
年(卷),期 2020(11),5
年度 2020
页码 -1
总页数 14
原文格式 PDF
正文语种
中图分类基础医学;
关键词
China; Dulaglutide; Glimepiride; Type 2 diabetes;

机译：中国;杜拉鲁肽;格列美脲;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Na?ve Chinese patients with Type?2 Diabetes: A Post Hoc Analysis of AWARD-CHN1 [J] . Yi Ming Li, Li Hui Zhang, Xue Jun Li, Diabetes therapy . 2020,第5期

机译：杜拉蛋白质单疗法的疗效和安全性与口腔抗血糖药物治疗 - Na've型患者的胶质脂糖苷e相比？2糖尿病患者：奖励 - CHN1的后HOC分析
2. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type?2 diabetes: Post‐hoc analyses of a randomized, double‐blind, phase?III study [J] . Li Xin Shi, Xiao Min Liu, Yong Quan Shi, Journal of diabetes investigation. . 2020,第1期

机译：杜拉蛋白单疗法的疗效和安全性与中国患者患者的肺纤维（2型糖尿病患者）：随机，双盲，阶段的HOC分析III研究
3. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East‐Asian patients with type 2 diabetes in a multicentre, double‐blind, randomized, parallel‐arm, active comparator, phase III trial [J] . Chen Yu Hong, Huang Chien‐Ning, Cho Young Min, Diabetes, obesity & metabolism . 2018,第9期

机译：杜拉蛋白单疗法的疗效和安全性与多期，双盲，随机，平行，有效的比较器，III期试验中的2型糖尿病患者的肺血管肽相比
4. Nonadherence to Oral Antihyperglycemic Agents: Subsequent Hospitalization and Mortality among Patients with Type 2 Diabetes in Clinical Practice [C] . Vivienne J. Zhu, Wanzhu Tu, Marc B. Rosenman, MEDINFO . 2015

机译：口服抗血糖剂：临床实践中2型糖尿病患者的随后住院和死亡率
5. Risk of Any Hypoglycemia with New Antihyperglycemic Agents in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis [D] . Kamalinia, Sanaz. 2019

机译：患有2型糖尿病患者的新抗血糖药物的任何低血糖症的风险：系统审查和荟萃分析
6. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post‐hoc analyses of a randomized double‐blind phase III study [O] . Li Xin Shi, Xiao Min Liu, Yong Quan Shi, 2020

机译：杜格鲁肽单药与格列美脲相比在中国2型糖尿病患者中的疗效和安全性：一项随机双盲III期研究的事后分析
7. Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1 [O] . Yi Ming Li, Li Hui Zhang, Xue Jun Li, 2020

机译：杜拉蛋白质单疗法的疗效和安全性与口腔抗血糖药物中的肺血管肽 - 奈韦夫患者2型糖尿病患者：奖励 - CHN1的后HOC分析

Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1

摘要

著录项

相似文献

相关主题

期刊订阅